Genetics of Dyslipidemia and Ischemic Heart Disease (Q38692446)

5 September 2017

title

Genetics of Dyslipidemia and Ischemic Heart Disease (English)

1 reference

5 September 2017

1 reference

Kavita Sharma

1 reference

5 September 2017

Ragavendra R Baliga

series ordinal

1 reference

5 September 2017

publication date

1 May 2017

1 reference

Current cardiology reports

5 September 2017

published in

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

HDL-cholesterol: perfection is the enemy of good?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

A novel cellular phenotype for familial hypercholesterolemia due to a defect in polarized targeting of LDL receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Phenotypic variability in familial hypercholesterolaemia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Current management of severe homozygous hypercholesterolaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Familial Hypercholesterolaemia in the Era of Genetic Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Novel Therapies for Familial Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

PCSK9 inhibitors in the prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Recent advances in the treatment of homozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Homozygous familial hypercholesterolaemia presenting with cutaneous xanthomas: response to liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Lipoprotein(a): resurrected by genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Mendelian randomization: nature's randomized trial in the post-genome era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Structure, function, and genetics of lipoprotein (a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Genetic variants associated with Lp(a) lipoprotein level and coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Latest developments in the treatment of lipoprotein (a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Emerging therapeutic agents to lower lipoprotein (a) levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

The genetic architecture of the familial hyperlipidaemia syndromes: rare mutations and common variants in multiple genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Combined hyperlipidemia: familial but not (usually) monogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

National Lipid Association Annual Summary of Clinical Lipidology 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Common variants associated with plasma triglycerides and risk for coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Remnant cholesterol as a causal risk factor for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

The evaluation of cascade testing for familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-017-0855-9

21 January 2018

1 reference

12 December 2020

Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight

1 reference

12 December 2020

Induction of oxygen free radical generation in human monocytes by lipoprotein(a)

1 reference

12 December 2020

Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages

1 reference

12 December 2020

Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it

1 reference

12 December 2020

Preemptive liver transplantation in a child with familial hypercholesterolemia

1 reference

12 December 2020

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

1 reference

12 December 2020

10.1007/S11886-017-0855-9

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1084971764

0 references

1 reference